I

Intensity Therapeutics Inc
NASDAQ:INTS

Watchlist Manager
Intensity Therapeutics Inc
NASDAQ:INTS
Watchlist
Price: 0.4155 USD -4.28%
Market Cap: 25m USD

Intensity Therapeutics Inc
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Intensity Therapeutics Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
I
Intensity Therapeutics Inc
NASDAQ:INTS
Other
-$653k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
$47m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other
-$6.5B
CAGR 3-Years
-244%
CAGR 5-Years
-115%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Other
-$9.6B
CAGR 3-Years
-380%
CAGR 5-Years
-174%
CAGR 10-Years
-31%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$371.2m
CAGR 3-Years
-30%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other
-$276.6m
CAGR 3-Years
31%
CAGR 5-Years
19%
CAGR 10-Years
4%
No Stocks Found

Intensity Therapeutics Inc
Glance View

Market Cap
25m USD
Industry
Biotechnology

Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Westport, Connecticut and currently employs 3 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing an approach to treat solid tumor cancers. The company leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The firm's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. The company also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725).

INTS Intrinsic Value
Not Available

See Also

What is Intensity Therapeutics Inc's Other?
Other
-653k USD

Based on the financial report for Dec 31, 2024, Intensity Therapeutics Inc's Other amounts to -653k USD.

Back to Top